HTG Prepares To Test Investor Appetite For Diagnostics
HTG Molecular Diagnostics Inc. fine-tuned its initial public offering plans Monday as the company, which is backed by Novo A/S and Merck Capital Ventures, prepares to test investor appetite for the...To view the full article, register now.
Already a subscriber? Click here to view full article